{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:53:20Z","timestamp":1773874400327,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00702-025-03027-6","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T07:43:12Z","timestamp":1759131792000},"page":"461-470","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reduced cerebrospinal fluid taurine is associated with nigrostriatal dopaminergic deficits in drug-na\u00efve Parkinson\u2019s disease"],"prefix":"10.1007","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3400-585X","authenticated-orcid":false,"given":"Masahiro","family":"Mimori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Umehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Takatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiro","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Masui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiko","family":"Motegi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asako","family":"Onda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromasa","family":"Matsuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teppei","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Sakuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shusaku","family":"Omoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetaka","family":"Mitsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetomo","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"3027_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1600-0404.1986.tb03249.x","volume":"73","author":"K Araki","year":"1986","unstructured":"Araki K, Takino T, Ida S, Kuriyama K (1986) Alteration of amino acids in cerebrospinal fluid from patients with Parkinson\u2019s disease and spinocerebellar degeneration. Acta Neurol Scand 73:105\u2013110. https:\/\/doi.org\/10.1111\/j.1600-0404.1986.tb03249.x","journal-title":"Acta Neurol Scand"},{"key":"3027_CR2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/s0140-6736(23)01419-8","volume":"403","author":"Y Ben-Shlomo","year":"2024","unstructured":"Ben-Shlomo Y, Darweesh S, Llibre-Guerra J et al (2024) The epidemiology of Parkinson\u2019s disease. Lancet 403:283\u2013292. https:\/\/doi.org\/10.1016\/s0140-6736(23)01419-8","journal-title":"Lancet"},{"key":"3027_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2967\/jnmt.118.222349","volume":"47","author":"JE Brogley","year":"2019","unstructured":"Brogley JE (2019) DaTQUANT: the future of diagnosing Parkinson disease. J Nucl Med Technol 47:21\u201326. https:\/\/doi.org\/10.2967\/jnmt.118.222349","journal-title":"J Nucl Med Technol"},{"key":"3027_CR4","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1093\/brain\/awab076","volume":"144","author":"L Cal\u00f3","year":"2021","unstructured":"Cal\u00f3 L, Hidari E, Wegrzynowicz M et al (2021) CSP\u03b1 reduces aggregates and rescues striatal dopamine release in \u03b1-synuclein transgenic mice. Brain 144:1661\u20131669. https:\/\/doi.org\/10.1093\/brain\/awab076","journal-title":"Brain"},{"key":"3027_CR5","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/mds.20112","volume":"19","author":"AM Catafau","year":"2004","unstructured":"Catafau AM, Tolosa E, Group DCUPSS (2004) Impact of dopamine transporter SPECT using 123I-ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Mov Disord 19:1175\u20131182. https:\/\/doi.org\/10.1002\/mds.20112","journal-title":"Mov Disord"},{"key":"3027_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0468-2","volume":"9","author":"Y Che","year":"2018","unstructured":"Che Y, Hou L, Sun F et al (2018) Taurine protects dopaminergic neurons in a mouse Parkinson\u2019s disease model through inhibition of microglial M1 polarization. Cell Death Dis 9:435. https:\/\/doi.org\/10.1038\/s41419-018-0468-2","journal-title":"Cell Death Dis"},{"key":"3027_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-1-4899-0117-0_20","volume":"442","author":"R Dawson","year":"1998","unstructured":"Dawson R, Tang E, Shih D et al (1998) Taurine 3, cellular and regulatory mechanisms. Adv Exp Med Biol 442:155\u2013162. https:\/\/doi.org\/10.1007\/978-1-4899-0117-0_20","journal-title":"Adv Exp Med Biol"},{"key":"3027_CR8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/s0361-9230(99)00003-9","volume":"48","author":"R Dawson","year":"1999","unstructured":"Dawson R, Pelleymounter MA, Cullen MJ et al (1999) An age-related decline in striatal taurine is correlated with a loss of dopaminergic markers. Brain Res Bull 48:319\u2013324. https:\/\/doi.org\/10.1016\/s0361-9230(99)00003-9","journal-title":"Brain Res Bull"},{"key":"3027_CR9","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1023\/a:1024255208563","volume":"28","author":"S Engelborghs","year":"2003","unstructured":"Engelborghs S, Marescau B, Deyn PPD (2003) Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson\u2019s disease. Neurochem Res 28:1145\u20131150. https:\/\/doi.org\/10.1023\/a:1024255208563","journal-title":"Neurochem Res"},{"key":"3027_CR10","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman S, Wenning GK, Low PA et al (2008) Second consensus statement on the diagnosis of multiple system atrophySYMBOL. Neurology 71:670\u2013676. https:\/\/doi.org\/10.1212\/01.wnl.0000324625.00404.15","journal-title":"Neurology"},{"key":"3027_CR11","doi-asserted-by":"publisher","first-page":"16084","DOI":"10.1038\/srep16084","volume":"5","author":"R Hajj","year":"2015","unstructured":"Hajj R, Milet A, Toulorge D et al (2015) Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson\u2019s disease. Sci Rep 5:16084. https:\/\/doi.org\/10.1038\/srep16084","journal-title":"Sci Rep"},{"key":"3027_CR12","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1007\/s00415-013-7126-5","volume":"260","author":"MK Herbert","year":"2013","unstructured":"Herbert MK, Kuiperij HB, Bloem BR, Verbeek MM (2013) Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson\u2019s disease and controls. J Neurol 260:3129\u20133133. https:\/\/doi.org\/10.1007\/s00415-013-7126-5","journal-title":"J Neurol"},{"key":"3027_CR13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.brainres.2005.02.066","volume":"1043","author":"W Hilgier","year":"2005","unstructured":"Hilgier W, Oja SS, Saransaari P, Albrecht J (2005) Taurine prevents ammonia-induced accumulation of cyclic GMP in rat striatum by interaction with GABAA and glycine receptors. Brain Res 1043:242\u2013246. https:\/\/doi.org\/10.1016\/j.brainres.2005.02.066","journal-title":"Brain Res"},{"key":"3027_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.70563","volume":"15","author":"P Hodgson","year":"2025","unstructured":"Hodgson P, Jordan A, Sinani C, Charura D (2025) Examining the relationship between physical function and anxiety\/depression in Parkinson\u2019s. Brain Behav 15:e70563. https:\/\/doi.org\/10.1002\/brb3.70563","journal-title":"Brain Behav"},{"key":"3027_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.nutres.2018.11.001","volume":"62","author":"JR Hoffman","year":"2019","unstructured":"Hoffman JR, Gepner Y, Cohen H (2019) \u0392-alanine supplementation reduces anxiety and increases neurotrophin expression in both young and older rats. Nutr Res 62:51\u201363. https:\/\/doi.org\/10.1016\/j.nutres.2018.11.001","journal-title":"Nutr Res"},{"key":"3027_CR16","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1111\/ene.14470","volume":"27","author":"FJ Jim\u00e9nez-Jim\u00e9nez","year":"2020","unstructured":"Jim\u00e9nez-Jim\u00e9nez FJ, Alonso-Navarro H, Garc\u00eda-Mart\u00edn E, Ag\u00fandez JAG (2020) Cerebrospinal and blood levels of amino acids as potential biomarkers for Parkinson\u2019s disease: review and meta-analysis. Eur J Neurol 27:2336\u20132347. https:\/\/doi.org\/10.1111\/ene.14470","journal-title":"Eur J Neurol"},{"key":"3027_CR17","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1046\/j.1471-4159.2002.01223.x","volume":"83","author":"Y Kang","year":"2002","unstructured":"Kang Y, Ohtsuki S, Takanaga H et al (2002) Regulation of taurine transport at the blood\u2013brain barrier by tumor necrosis factor\u2010\u03b1, taurine and hypertonicity. J Neurochem 83:1188\u20131195. https:\/\/doi.org\/10.1046\/j.1471-4159.2002.01223.x","journal-title":"J Neurochem"},{"key":"3027_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/syn.890090107","volume":"9","author":"MJ Kaufman","year":"1991","unstructured":"Kaufman MJ, Madras BK (1991) Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson\u2019s-diseased striatum. Synapse 9:43\u201349. https:\/\/doi.org\/10.1002\/syn.890090107","journal-title":"Synapse"},{"key":"3027_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/0-306-46838-7_13","volume":"483","author":"E Kibayashi","year":"2002","unstructured":"Kibayashi E, Yokogoshi H, Mizue H et al (2002) Taurine 4, taurine and excitable tissues. Adv Exp Med Biol 483:137\u2013142. https:\/\/doi.org\/10.1007\/0-306-46838-7_13","journal-title":"Adv Exp Med Biol"},{"key":"3027_CR20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1212\/WNL.26.5.489","volume":"26","author":"JPWF Lakke","year":"1976","unstructured":"Lakke JPWF, Teelken AW (1976) Amino acid abnormalities in cerebrospinal fluid of patients with parkinsonism and ext rapyram idal disorders. Neurology 26:483\u2013492","journal-title":"Neurology"},{"key":"3027_CR21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.neuro.2005.01.008","volume":"26","author":"E-SY Lee","year":"2005","unstructured":"Lee E-SY, Chen H, Soliman KFA, Charlton CG (2005) Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology 26:361\u2013371. https:\/\/doi.org\/10.1016\/j.neuro.2005.01.008","journal-title":"Neurotoxicology"},{"key":"3027_CR22","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/s41467-018-03802-y","volume":"9","author":"N Lozovaya","year":"2018","unstructured":"Lozovaya N, Eftekhari S, Cloarec R et al (2018) Gabaergic inhibition in dual-transmission cholinergic and gabaergic striatal interneurons is abolished in Parkinson disease. Nat Commun 9:1422. https:\/\/doi.org\/10.1038\/s41467-018-03802-y","journal-title":"Nat Commun"},{"key":"3027_CR23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1471-4159.1977.tb09621.x","volume":"29","author":"EHF McGale","year":"1977","unstructured":"McGale EHF, Pye IF, Stonier C et al (1977) Studies of the inter-relationship between cerebrospinal fluid and plasma amino acid concentrations in normal individuals. J Neurochem 29:291\u2013297. https:\/\/doi.org\/10.1111\/j.1471-4159.1977.tb09621.x","journal-title":"J Neurochem"},{"key":"3027_CR24","doi-asserted-by":"publisher","first-page":"1271203","DOI":"10.3389\/fphar.2023.1271203","volume":"14","author":"P Meera","year":"2023","unstructured":"Meera P, Uusi-Oukari M, Lipshutz GS, Wallner M (2023) GABAA receptors as plausible molecular targets and mediators for taurine and homotaurine actions. Front Pharmacol 14:1271203. https:\/\/doi.org\/10.3389\/fphar.2023.1271203","journal-title":"Front Pharmacol"},{"key":"3027_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0306-4522(94)90002-7","volume":"63","author":"IJ Mitchell","year":"1994","unstructured":"Mitchell IJ, Lawson S, Moser B et al (1994) Glutamate-induced apoptosis results in a loss of striatal neurons in the parkinsonian rat. Neuroscience 63:1\u20135. https:\/\/doi.org\/10.1016\/0306-4522(94)90002-7","journal-title":"Neuroscience"},{"key":"3027_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jphs.2023.11.003","volume":"154","author":"T Miyazaki","year":"2024","unstructured":"Miyazaki T (2024) Identification of a novel enzyme and the regulation of key enzymes in mammalian taurine synthesis. J Pharmacol Sci 154:9\u201317. https:\/\/doi.org\/10.1016\/j.jphs.2023.11.003","journal-title":"J Pharmacol Sci"},{"key":"3027_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/s0022-510x(97)00069-5","volume":"150","author":"JA Molina","year":"1997","unstructured":"Molina JA, Jim\u00e9nez-Jim\u00e9nez FJ, G\u00f3mez P et al (1997) Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson\u2019s disease. J Neurol Sci 150:123\u2013127. https:\/\/doi.org\/10.1016\/s0022-510x(97)00069-5","journal-title":"J Neurol Sci"},{"key":"3027_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.expneurol.2017.05.009","volume":"295","author":"S Moreira","year":"2017","unstructured":"Moreira S, Fonseca I, Nunes MJ et al (2017) Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson\u2019s disease. Exp Neurol 295:77\u201387. https:\/\/doi.org\/10.1016\/j.expneurol.2017.05.009","journal-title":"Exp Neurol"},{"key":"3027_CR29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/s0140-6736(23)01478-2","volume":"403","author":"HR Morris","year":"2024","unstructured":"Morris HR, Spillantini MG, Sue CM, Williams-Gray CH (2024) The pathogenesis of Parkinson\u2019s disease. Lancet 403:293\u2013304. https:\/\/doi.org\/10.1016\/s0140-6736(23)01478-2","journal-title":"Lancet"},{"key":"3027_CR30","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1471-4159.1991.tb02580.x","volume":"56","author":"HB Niznik","year":"1991","unstructured":"Niznik HB, Fogel EF, Fassos FF, Seeman P (1991) The dopamine transporter is absent in Parkinsonian putamen and reduced in the caudate nucleus. J Neurochem 56:192\u2013198. https:\/\/doi.org\/10.1111\/j.1471-4159.1991.tb02580.x","journal-title":"J Neurochem"},{"key":"3027_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jpsychires.2017.09.014","volume":"96","author":"S Ogawa","year":"2018","unstructured":"Ogawa S, Koga N, Hattori K et al (2018) Plasma amino acid profile in major depressive disorder: analyses in two independent case-control sample sets. J Psychiatr Res 96:23\u201332. https:\/\/doi.org\/10.1016\/j.jpsychires.2017.09.014","journal-title":"J Psychiatr Res"},{"key":"3027_CR32","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1136\/jnnp-2018-317964","volume":"90","author":"Y Ohsawa","year":"2019","unstructured":"Ohsawa Y, Hagiwara H, Nishimatsu S et al (2019) Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial. J Neurol Neurosurg Psychiatry 90:529. https:\/\/doi.org\/10.1136\/jnnp-2018-317964","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3027_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2024.115397","volume":"480","author":"JE Onuelu","year":"2025","unstructured":"Onuelu JE, Ben-Azu B, Adebayo OG et al (2025) Taurine, an essential amino acid, attenuates rotenone-induced Parkinson\u2019s disease in rats by inhibiting alpha-synuclein aggregation and augmenting dopamine release. Behav Brain Res 480:115397. https:\/\/doi.org\/10.1016\/j.bbr.2024.115397","journal-title":"Behav Brain Res"},{"key":"3027_CR34","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/s0309-1740(03)00181-5","volume":"66","author":"RW Purchas","year":"2004","unstructured":"Purchas RW, Rutherfurd SM, Pearce PD et al (2004) Concentrations in beef and lamb of taurine, carnosine, coenzyme Q10, and creatine. Meat Sci 66:629\u2013637. https:\/\/doi.org\/10.1016\/s0309-1740(03)00181-5","journal-title":"Meat Sci"},{"key":"3027_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11011-025-01542-9","volume":"40","author":"SM Razavi","year":"2025","unstructured":"Razavi SM, Esmaealzadeh N, Ataei M et al (2025) The effects of ursodeoxycholic acid on Parkinson\u2019s disease, a mechanistic review of the recent evidence. Metab Brain Dis 40:115. https:\/\/doi.org\/10.1007\/s11011-025-01542-9","journal-title":"Metab Brain Dis"},{"key":"3027_CR36","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/mdc3.12462","volume":"4","author":"C Rodr\u00edguez-Bl\u00e1zquez","year":"2017","unstructured":"Rodr\u00edguez-Bl\u00e1zquez C, Alvarez M, Arakaki T et al (2017) Self-assessment of disability in Parkinson\u2019s disease: the MDS-UPDRS part II versus clinician-based ratings. Mov Disord Clin Pract 4:529\u2013535. https:\/\/doi.org\/10.1002\/mdc3.12462","journal-title":"Mov Disord Clin Pract"},{"key":"3027_CR37","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1016\/j.bbadis.2017.06.004","volume":"1863","author":"AI Rosa","year":"2017","unstructured":"Rosa AI, Fonseca I, Nunes MJ et al (2017) Novel insights into the antioxidant role of tauroursodeoxycholic acid in experimental models of Parkinson\u2019s disease. Biochim Biophys Acta 1863:2171\u20132181. https:\/\/doi.org\/10.1016\/j.bbadis.2017.06.004","journal-title":"Biochim Biophys Acta"},{"key":"3027_CR38","doi-asserted-by":"publisher","first-page":"9139","DOI":"10.1007\/s12035-018-1062-4","volume":"55","author":"AI Rosa","year":"2018","unstructured":"Rosa AI, Duarte-Silva S, Silva-Fernandes A et al (2018) Tauroursodeoxycholic acid improves motor symptoms in a mouse model of Parkinson\u2019s disease. Mol Neurobiol 55:9139\u20139155. https:\/\/doi.org\/10.1007\/s12035-018-1062-4","journal-title":"Mol Neurobiol"},{"key":"3027_CR39","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s00210-003-0776-6","volume":"368","author":"J Salim\u00e4ki","year":"2003","unstructured":"Salim\u00e4ki J, Scriba G, Piepponen TP et al (2003) The effects of systemically administered taurine and N-pivaloyltaurine on striatal extracellular dopamine and taurine in freely moving rats. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 368:134\u2013141. https:\/\/doi.org\/10.1007\/s00210-003-0776-6","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"3027_CR40","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.neuint.2017.01.007","volume":"105","author":"A Stefani","year":"2017","unstructured":"Stefani A, Pierantozzi M, Olivola E et al (2017) Homovanillic acid in CSF of mild stage Parkinson\u2019s disease patients correlates with motor impairment. Neurochem Int 105:58\u201363. https:\/\/doi.org\/10.1016\/j.neuint.2017.01.007","journal-title":"Neurochem Int"},{"key":"3027_CR41","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/0006-2952(95)02046-2","volume":"50","author":"I Tamai","year":"1995","unstructured":"Tamai I, Senmaru M, Terasaki T, Tsuji A (1995) Na+- and Cl\u2212-dependent transport of taurine at the blood-brain barrier. Biochem Pharmacol 50:1783\u20131793. https:\/\/doi.org\/10.1016\/0006-2952(95)02046-2","journal-title":"Biochem Pharmacol"},{"key":"3027_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2024.101040","volume":"61","author":"Y Tega","year":"2025","unstructured":"Tega Y, Kawauchi Y, Akanuma S et al (2025) In vitro characterization of taurine transport using the human brain microvascular endothelial cell line as a human blood-brain barrier model. Drug Metab Pharmacokinet 61:101040. https:\/\/doi.org\/10.1016\/j.dmpk.2024.101040","journal-title":"Drug Metab Pharmacokinet"},{"key":"3027_CR43","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00259-006-0155-x","volume":"33","author":"L Tossici-Bolt","year":"2006","unstructured":"Tossici-Bolt L, Hoffmann SMA, Kemp PM et al (2006) Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging 33:1491\u20131499. https:\/\/doi.org\/10.1007\/s00259-006-0155-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3027_CR44","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/1742-2094-9-124","volume":"9","author":"Q Wang","year":"2012","unstructured":"Wang Q, Shin E-J, Nguyen X-KT et al (2012) Endogenous dynorphin protects against neurotoxin-elicited nigrostriatal dopaminergic neuron damage and motor deficits in mice. J Neuroinflammation 9:124. https:\/\/doi.org\/10.1186\/1742-2094-9-124","journal-title":"J Neuroinflammation"},{"key":"3027_CR45","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s007020170019","volume":"108","author":"A Winogrodzka","year":"2001","unstructured":"Winogrodzka A, Bergmans P, Booij J et al (2001) [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson\u2019s disease. J Neural Transm 108:1011\u20131019. https:\/\/doi.org\/10.1007\/s007020170019","journal-title":"J Neural Transm"},{"key":"3027_CR46","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.3945\/jn.114.196105","volume":"144","author":"T Yoshikawa","year":"2014","unstructured":"Yoshikawa T, Nakamura T, Shibakusa T et al (2014) Insufficient intake of L-histidine reduces brain histamine and causes anxiety-like behaviors in male mice. J Nutr 144:1637\u20131641. https:\/\/doi.org\/10.3945\/jn.114.196105","journal-title":"J Nutr"},{"key":"3027_CR47","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3109\/00207454.2015.1051046","volume":"126","author":"L Zhang","year":"2016","unstructured":"Zhang L, Yuan Y, Tong Q et al (2016) Reduced plasma taurine level in Parkinson\u2019s disease: association with motor severity and levodopa treatment. Int J Neurosci 126:630\u2013636. https:\/\/doi.org\/10.3109\/00207454.2015.1051046","journal-title":"Int J Neurosci"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03027-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-03027-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03027-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:14:32Z","timestamp":1773846872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-025-03027-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3027"],"URL":"https:\/\/doi.org\/10.1007\/s00702-025-03027-6","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have any conflicts of interest related to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}